China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved to treat this indication\u2014Roche\u2019s Herceptin as the first-line standard of care for HER2-positive gastric and GEJ adenocarcinoma patients, Jiangsu Hengrui Medicine\u2019s AiTan and BMS\u2019s Opdivo for third-line gastric and GEJ adenocarcinoma patients, and Merck\u2019s Keytruda and Jiangsu Hengrui Medicine\u2019s AiRuiKa for second-line esophageal squamous cell carcinoma patients. Several novel targeted therapies\u2014including VEGF2 inhibitors (Eli Lilly\u2019s Cyramza and Chi-Med\u2019s Elunate), a claudin inhibitor (Ganymed\u2019s zolbetuximab), and immune checkpoint inhibitors (Innovent Biologics\u2019 Tyvyt, BeiGene\u2019s Baizean, and CStone Pharmaceuticals\u2019s CS1001)\u2014are in preregistration or late-phase trials. The launch and uptake of these agents will lead to significant growth of the gastroesophageal cancer therapy market over the 2020-2030 period. However, the need for additional, effective targeted therapies will remain high, representing a lucrative commercial opportunity for developers.<\/p>\n
QUESTIONS ANSWERED<\/p>\n
\u00b7 How large is China\u2019s drug-treatable gastroesophageal cancer population, and how will drug-treatment rates change during the forecast period?<\/p>\n
\u00b7 Which are the most commercially relevant drugs in China\u2019s gastroesophageal cancer market and why? What are interviewed experts\u2019 insights into current treatment options?<\/p>\n
\u00b7 What are the key market access considerations for therapies in the gastroesophageal cancer pipeline in China? What sales \/ uptake could they secure in gastroesophageal cancer? What are interviewed experts\u2019 opinions of key emerging therapies?<\/p>\n
\u00b7 What are the key drivers and constraints in the gastroesophageal cancer therapy market of China, and how will the market evolve over the forecast period?<\/p>\n
PRODUCT DESCRIPTION<\/p>\n
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.<\/p>\n","protected":false},"template":"","class_list":["post-390183","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gastric-cancer","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390183","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390183\/revisions"}],"predecessor-version":[{"id":576502,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390183\/revisions\/576502"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}